In a nutshell The authors evaluated the efficacy and safety of pyrotinib (Irene), for the treatment of HER2- positive metastatic breast cancer (MBC) in a real-world setting. The authors observed that pyrotinib was effective and well tolerated by patients. Some background Breast cancer (BC) is the most common tumor in women...
Read More
In a nutshell This article reviewed new studies on focal therapy (FT) in patients with localized prostate cancer (PCa), with a focus on treatment effectiveness. Some background FT includes alternative, non-invasive methods for treating PCa. High-intensity focused ultrasound (HIFU) is a radiation-free technique that uses high-frequency ultrasound...
Read More
In a nutshell This study assessed the effect of foot-ankle flexibility and resistance exercises in the prevention and recurrence of plantar foot-diabetic ulcers. The authors concluded that foot-ankle flexibility and resistance exercises can reduce the recurrence of plantar foot-diabetic ulcers and improve diabetic neuropathy (DN; nerve damage) and...
Read More
In a nutshell This study aims to investigate the long-term effectiveness and safety of the rituximab biosimilar CT-P10 (Truxima) in combination with cyclophosphamide (Cytoxan), vincristine (Oncovin), and prednisone (Deltasone) (CVP) compared with rituximab (Rituxan) for the treatment of advanced-stage follicular lymphoma (FL). The...
Read More
In a nutshell This study investigated the effectiveness and safety of panitumumab (Vectibix) when added to maintenance therapy with fluorouracil (Adrucil) and folinic acid (Leucovirin) (FU/FA) in patients with RAS wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with FU/FA plus panitumumab was safe and...
Read More
In a nutshell This study compared the effectiveness and safety outcomes of single and double immune checkpoint inhibitors (ICI)-based treatments in patients with advanced non-small-cell lung cancer (NSCLC). The data showed that the effectiveness and safety of both single and double ICI-based treatments were similar and higher...
Read More
In a nutshell This study evaluated the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for the treatment of patients with metastatic HER2-positive breast cancer (BC). The data showed that THP (taxanes + trastuzumab + pertuzumab) was the best first-line treatment, while Trastuzumab emtansine (T-DM1; Kadcycla) and...
Read More
In a nutshell This review aimed to investigate the prognostic value of minimal residual disease (MRD) in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review concluded that MRD is a good predictor of outcomes in these patients. Some background Ph+ ALL is an aggressive type of...
Read More
In a nutshell This study aimed to review the safety and effectiveness of three chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (AXI; Yescarta), tisagenlecleucel (TIS; Kymriah), and lisocabtagene maraleucel (LIS; Breyanzi), for the treatment of blood cancers. This...
Read More
In a nutshell This study aimed to review the safety and effectiveness of three chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (AXI; Yescarta), tisagenlecleucel (TIS; Kymriah), and lisocabtagene maraleucel (LIS; Breyanzi), for the treatment of blood cancers. This study concluded that AXI and TIS showed very good...
Read More
In a nutshell This study aimed to review the safety and effectiveness of three chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (AXI; Yescarta), tisagenlecleucel (TIS; Kymriah), and lisocabtagene maraleucel (LIS; Breyanzi), for the treatment of blood cancers. This study concluded that AXI and TIS showed very good...
Read More
In a nutshell This study aimed to investigate pyrotinib (Irene)-based therapy as a treatment for patients with HER2-positive advanced breast cancer. This study concluded that pyrotinib-based therapy was safe and effective in these patients, particularly in those that received 2 or fewer therapies and received capecitabine...
Read More
